An interventional study of Physiological Pacing Upgrade (Conduction System Pacing or Biventricular Pacing) and Continued RV Pacing (Right Ventricular Pacing) in Pacing-Induced Cardiomyopathy and Heart Failure, sponsored by Imperial College London. Recruiting at 12 sites in United Kingdom. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-23.
Sponsored by Imperial College London · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 29 studies in Heart Failure by Imperial College London — 7 open to participants now, 8 under way, none of them phase 3. Heart Failure · Imperial College London.
Among the 29 studies in Heart Failure by Imperial College London, this one is the 6th largest by planned enrollment of the 18 interventional ones that give a count, is one of 5 that started in 2023, is one of 11 with no phase, and was the 26th registered.
6,340 studies on the registry are indexed under Heart Failure; 1,397 are open to participants now.
Browse Heart Failure studies →7 of the 29 studies in Heart Failure by Imperial College London are open now, in 1 country. Recruiting first, the newest first:
Imperial College London · Sites in United Kingdom
Ages 18+
Imperial College London · Sites in United Kingdom
Ages 18–90
Imperial College London · Sites in United Kingdom
Ages 18+
Imperial College London · Sites in United Kingdom
Ages 18–85
Imperial College London · Sites in United Kingdom
Ages 18+
By country, each count listing its studies:
Of the 968 Heart Failure studies recruiting now, 691 (71%) set no upper age limit and 90 (9%) stop at 75 or younger; 64 take children under 18; 97 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
29 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 3 · Phase 3 1
First in 2006; this study’s year is marked. 5 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 155 is above the median of 76 across 4,053 interventional studies indexed under Heart Failure.
Median enrollment 55 across the 18 interventional studies, 100 across the 11 observational. Of the 15 that completed or were terminated, 6 (40%) have results posted.
This tab as a report to print or save as PDF → With an account.
Imperial College London is the lead sponsor of 844 studies on the registry; 181 are open to participants now.
Of its 9 completed or terminated interventional studies of FDA-regulated products, 6 (67%) have results posted.
1 of the studies in Heart Failure by Imperial College London that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07057466Imperial College LondonProspective Evaluation of AI-ECG for SHD Detection | 2027-05-03 |
Add it to your calendar (.ics) → With an account.
Among the 29 studies in Heart Failure by Imperial College London, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Guidelines for patients having first-time implants advocate that even when heart function is only mildly impaired, modern pacing approaches should be utilised to avoid the potentially damaging effects of RV pacing to preventing symptoms from pacing induced or worsened cardiomyopathy.
However, once a traditional (RV) pacemaker is implanted, development of impaired heart function does not prompt a device upgrade. Even at the end of battery life, physicians simply replace it like-for-like.
This trial tests whether such patients have better symptoms and quality of life if changed to a modern physiological pacing strategy from the traditional RV pacing approach.
In this crossover trial, participants will be upgraded to a physiological pacing strategy.
After their procedure, they will have a one-month run-in period to recover from the procedure (their pacemaker will be programmed to continued RV pacing).
They will be have 2 one-month blinded time periods, randomised to physiological pacing or right ventricular pacing alternately. They will subsequently undergo two six-month blinded randomised time periods.
Patients will document symptoms monthly on a mobile phone application or computer. At the end of each time period, they will have measurements of heart function, a walking test and quality-of-life questionnaires including the SF-36 questionnaire.
The investigators hypothesise that upgrading to physiological pacing strategies will improve patients' quality of life.
Patients with an RV pacemaker and 35-50% and a high burden of right ventricular pacing (>40%) who are clinically indicated for a cardiac resynchronisation therapy upgrade procedure and:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The approach for physiological pacing will be either His bundle pacing or left bundle pacing at the operator's discretion. If both of these are not achieved biventricular pacing will be performed.
Device: Physiological Pacing Upgrade (Conduction System Pacing or Biventricular Pacing)
Right ventricular pacing (apical or septal lead locations as per the implanting physicians' normal practice)
Device: Continued RV Pacing (Right Ventricular Pacing)
The approach for physiological pacing upgrade will be either His bundle pacing or left bundle pacing at the operator's discretion. If both of these are not achieved biventricular pacing will be performed.
Right ventricular pacing (apical or septal lead locations as per the implanting physicians' normal practice).
SF-36 (Short Form 36 Health Survey Questionnaire) Physical Component Summary
Time frame: From date of baseline, until end of trial follow-up at fourteen months post-baseline
Left ventricular ejection fraction
(% ejection fraction)
Time frame: From date of baseline, until end of trial follow-up at fourteen months
Left ventricular end systolic volume
(millilitres)
Time frame: From date of baseline, until end of trial follow-up at fourteen months
Minnesota Living with Heart Failure Questionnaire
Time frame: From date of baseline, until end of trial follow-up at fourteen months
Six-minute walk test
Measured in distance in metres
Time frame: From date of baseline, until end of trial follow-up at fourteen months
Atrial fibrillation
(atrial fibrillation percentage burden as measured by pacemaker device - %)
Time frame: From date of baseline, until end of trial follow-up at fourteen months
Patient preference based on blinded symptomatic preference
Time frame: At 2 months following baseline and 14 months following baseline visit
EQ-5D Questionnaire
EQ-5D is the name of the instrument and is not an acronym. The EQ-5D-5L consists of 2 pages: the EQ-5D descriptive system and the EQ 'visual analogue scale' (EQ VAS). The descriptive system is made up of 5 sections: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each has 5 levels: no problems, slight problems, moderate problems, severe problems and extreme problems. The EQ VAS records the patient's self-rated health on a vertical visual analogue scale, where the endpoints are labelled 'The best health you can imagine' and 'The worst health you can imagine'. The VAS can be used as a quantitative (numerical) measure of health outcome that reflect the patient's own judgement. A high score on the VAS means a better outcome. A low score on the VAS means a worse outcome.
Time frame: From date of baseline, until end of trial follow-up at fourteen months post-baseline visit
Patient symptoms assessed on a scale of 0-100 monthly
This questionnaire will be sent to participants on a monthly basis for the duration of the study
Time frame: From date of baseline, until end of trial follow-up at fourteen months post-baseline visit
Safety endpoints
Device infections (requiring device extraction), pacing thresholds, need for lead revision or reimplantation, generator change, haematoma and pneumothorax
Time frame: From device implant date, assessed up to 15 months at the end of the trial (including a one-month run-in period post-procedure prior to the first baseline visit)
SF-36 (Short Form 36 Health Survey Questionnaire) Overall Score
Time frame: From date of baseline, until end of trial follow-up at fourteen months post baseline visit
SF-36 (Short Form 36 Health Survey Questionnaire) Individual Component Scores
Time frame: From date of baseline, until end of trial follow-up at fourteen months post baseline visit
BNP (B-type natriuretic peptide)
B-type natriuretic peptide blood test
Time frame: From date of baseline, until end of trial follow-up at fourteen months post baseline visit
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Started Sep 2023 (actual). Primary completion is estimated for Sep 2026, 36 months after the start.
Of 1,119 non-industry interventional studies with no phase under Heart Failure, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 50. This study's planned 36 months is above that.
Counting every sponsor, half of 1,355 studies reached it within 31 months; a quarter within 16 and three quarters within 52.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.